The Discovery of Dabigatran Etexilate
Joanne van Ryn(Boehringer Ingelheim (Brazil)), Andreas Clemens(Boehringer Ingelheim (Germany)), Ashley Goss(Boehringer Ingelheim (United States)), Norbert Hauel(Boehringer Ingelheim (Germany)), Wolfgang Wienen(Pharmazeutische Fabrik Dr. Reckeweg (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Henning Priepke(Boehringer Ingelheim (Germany))
Cited by 71
Related Papers
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383